Business
Assembly Biosciences Reports Fourth Quarter and Year End 2023 Financial Results and Recent Highlights
Four candidates planned to be in clinical development in 2024 with interim data from two studies anticipated by year end Clinical development timelines
About this update from Assembly Biosciences, Inc.
[{"type":"text","content":"Four candidates planned to be in clinical development in 2024 with interim data from two studies anticipated by year end Clinical development timelines accelerated for ABI-5366; now anticipating interim data from Phase 1a available in 3Q2024, initiation of Phase 1b in individuals with recurrent genital herpes by end of 2024 and interim Phase 1b data available in 1H2025Gilead Sciences, Inc. partnership supports advancement and strengthening of antiviral pipeline targeting serious viral diseases SOUTH SAN FRANCISCO, Calif., March 28, 2024 (GLOBE NEWSWIRE) -- Assembly Biosciences, Inc. (Nasdaq: ASMB), a biotechnology company developing innovative therapeutics targeting serious viral diseases, today reported financial results and recent highlights for the fourth quarter and year ended December 31, 2023. “Our progress in 2023 demonstrated our capacity to drive our expanded antiviral pipeline forward and our commitment to individuals suffering from life-impacting viral diseases,” said Jason Okazaki, chief executive officer and president of Assembly Bio. “With our long-term partnership in place with Gilead and the addition of Dr. Anuj Gaggar to our management team as CMO, we are well-positioned to make critical progress clinically across multiple programs in 2024 and look forward to sharing preliminary data on 5366 and 4334 later this year.” Fourth Quarter 2023 and Recent Highlights Entered a long-term partnership with Gilead to advance discovery and development of novel antiviral therapiesStrengthened the leadership team with the naming of Anuj Gaggar, MD, PhD, as chief medical officerFiled a clinical trial application for ABI-5366 to support initiation of Phase 1a/1b clinical studies Anticipated Milestones and Events By mid-year 2024: ABI-5366, a long-acting herpes simplex virus (HSV) helicase-primase inhibitor targeting recurrent genital herpes, is expected to enter a Phase 1a/1b studyABI-4334, a next-generation, highly potent capsid assembly modulator, is anticipated to enter a Phase 1b study in individuals with chronic hepatitis B virus infection Q3 2024: Interim clinical data from the ABI-5366 Phase 1a study portion expected to be available By the end of 2024: Interim clinical data from the ABI-4334 Phase 1b study expected to be availableThe Phase 1b portion of the ABI-5366 study, in individuals with recurrent genital herpes, is ...